Savas Takan^1,*, Gokmen Katipoglu²

Computer Systems Science and Engineering, Vol.46, No.2, pp. 2075-2089, 2023, DOI:10.32604/csse.2023.036791

Abstract A measure of the “goodness” or efficiency of the test suite is used to determine the proficiency of a test suite. The appropriateness of the test suite is determined through mutation analysis. Several Finite State Machine (FSM) mutants are produced in mutation analysis by injecting errors against hypotheses. These mutants serve as test subjects for the test suite (TS). The effectiveness of the test suite is proportional to the number of eliminated mutants. The most effective test suite is the one that removes the most significant number of mutants at the optimal time. It is difficult to determine the fault… More >

T. Edwin Ponraj^1,*, J. Charles²

Intelligent Automation & Soft Computing, Vol.36, No.1, pp. 1189-1203, 2023, DOI:10.32604/iasc.2023.033383

Abstract The mutation is a critical element in determining the proteins’ stability, becoming a core element in portraying the effects of a drug in the pharmaceutical industry. Doing wet laboratory tests to provide a better perspective on protein mutations is expensive and time-intensive since there are so many potential mutations, computational approaches that can reliably anticipate the consequences of amino acid mutations are critical. This work presents a robust methodology to analyze and identify the effects of mutation on a single protein structure. Initially, the context in a collection of words is determined using a knowledge graph for feature selection purposes.… More >

Hyeong Won Yu¹, Muhammad Afzal², Maqbool Hussain², Hyungju Kwon³, Young Joo Park⁴, June Young Choi^1,*, Kyu Eun Lee⁵

CMC-Computers, Materials & Continua, Vol.67, No.1, pp. 1241-1251, 2021, DOI:10.32604/cmc.2021.014910

Abstract Advances in technology are enabling gene mutations in papillary thyroid carcinoma (PTC) to be analyzed and clinical outcomes, such as recurrence, to be predicted. To date, the most common genetic mutation in PTC is in BRAF kinase (BRAF). However, whether mutations in other genes coincide with those in BRAF remains to be clarified. The aim of this study was to find mutations in other genes that co-exist with mutated BRAF, and to analyze their frequency and clinical relevance in PTC. Clinical and genetic data were collected from 213 PTC patients with a total of 36,572 mutation sites in 735 genes.… More >